MarginsXMarginsX
Home › Markets › Health Care › NRC

NRC Health (NRC)

NRC trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$26.33
-0.87% on the day
Market cap
$558.8M
Small cap
Revenue · 2025
$137.4M
-4.0% on 2024
Net income · 2025
$11.6M
8.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/70487/000143774926007002/0001437749-26-007002-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNRC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000070487
SEC industry codeServices-Commercial Physical & Biological Research
Incorporated inDE

Financials · 2025

LineValue
Revenue$137.4M
Net income$11.6M
Operating income$22.6M
Net margin8.4%
Operating margin16.4%
Revenue growth-4.0%
Cash$4.1M
Total assets$134.9M
P/E (computed)48.2×
P/S (computed)4.1×

Warning signs

Cash runway
Cash-flow positive
$3.6M cash at September 30, 2026
Share count, 1 year
-6.3%
2025-10-31 to 2026-10-31 · -13.6% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$98K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$3.6M cash; operating cash flow $5.9M a quarter.Report 2026-09-30
Shares outstanding21,221,538 (2026-10-31); 22,657,421 a year earlier; 24,558,330 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Omaha, Nebraska, United StatesPCAOB Form AP 2026-04-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $98K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$38.4M$4.7M$8.0M$3.6M$102.9M$143.8M10-Q 2026-11-04
Q2 2026
2026-06-30
$35.4M-$3.3M$1.4M$3.3M$90.0M$140.0M10-Q 2026-08-04
Q1 2026
2026-03-31
$34.8M$3.2M$7.2M$2.5M$74.0M$138.6M10-Q 2026-05-06
Q4 2025
2025-12-31
$35.2M$1.8M$7.2M$4.1M$79.0M$137.4M10-K 2026-03-05
Q3 2025
2025-09-30
$34.6M$4.1M$13.8M$2.2M$76.0M$139.1M10-Q 2026-11-04
Q2 2025
2025-06-30
$34.0M-$106K-$1.1M$5.3M$77.0M$140.3M10-Q 2026-08-04
Q1 2025
2025-03-31
$33.6M$5.8M$6.6M$2.5M$58.7M$141.3M10-Q 2026-05-06
Q4 2024
2024-12-31
$36.9M$6.6M$6.4M$4.2M$57.9M$143.1M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B7
424B72026-05-13
Latest annual report
FORM 10-K/A
10-K/A2026-04-28
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-10-27
Latest proxy
FORM DEFA14A
DEFA14A2026-05-08

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.7%
1 month+31.7%
3 months+24.6%
Year to date+41.5%
1 year+70.9%
From 52-week high-1.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
OABIOmniAb Inc.$4.89-0.41%$713.3M
ABSIAbsci Corporation$7.47-11.54%$1.3B
MXCTMaxCyte Inc.$1.18-0.84%$121.8M
ONMDOneMedNet Corp$4.86-8.99%$29.2M
ICLRICON plc$191.40-1.67%$14.7B
CRLCharles River Laboratories International Inc.$335.52-0.72%$16.1B
MEDPMedpace Holdings Inc.$648.20-0.88%$18.1B
INCYIncyte Corp.$120.27-0.58%$24.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier